Drug
Azd0120
Azd0120: highest development phase Phase 1/2, developed by Alexion, AstraZeneca. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Alexion, AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| AZD0120 NCT07081646 | Phase 1/2 | Relapsed AL Amyloidosis |
| AZD0120 NCT05850234 | Phase 1/2 | Relapsed/Refractory Multiple Myeloma |
| AZD0120 NCT07295847 | Phase 1/2 | Systemic Sclerosis |
Latest
Follow Azd0120 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.